These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16158740)

  • 1. [Chemotherapy of hormone-resistent cancer of the prostate].
    Matveev BP; Bukharkin BV; Kalinin SA
    Urologiia; 2005; (4):20-3. PubMed ID: 16158740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
    Bernardi D; Talamini R; Zanetti M; Simonelli C; Vaccher E; Spina M; Tirelli U
    Prostate Cancer Prostatic Dis; 2004; 7(1):45-9. PubMed ID: 14999238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of current chemotherapy in metastatic breast cancer resistant to anthracycline antibiotics].
    Moiseenko VM; Orlova RV
    Vopr Onkol; 1999; 45(4):445-8. PubMed ID: 10532109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
    Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
    Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
    Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Satraplatin in the treatment of hormone-refractory prostate cancer.
    Sternberg CN
    BJU Int; 2005 Nov; 96(7):990-4. PubMed ID: 16225514
    [No Abstract]   [Full Text] [Related]  

  • 9. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
    Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
    Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
    Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
    Sheen WC; Chen JS; Wang HM; Yang TS; Liaw CC; Lin YC
    Jpn J Clin Oncol; 2004 Jun; 34(6):337-41. PubMed ID: 15333686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
    J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
    Rezvani H; Haghighi S; Ghadyani M; Attarian H
    Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
    Protheroe A
    Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
    [No Abstract]   [Full Text] [Related]  

  • 18. [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
    Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):841-4. PubMed ID: 16770110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonging survival in prostate cancer: chemotherapy will have an important role.
    Parker C; Emberton M
    BJU Int; 2005 Jul; 96(1):2-3. PubMed ID: 15963108
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemotherapy of hormone refractory prostate carcinoma].
    Wirth MP; Nippgen J
    Urologe A; 2003 Nov; 42(11):1453-60. PubMed ID: 14624343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.